β-arrestin-mediated signaling improves the efficacy of therapeutics

Journal of Pharmacological Sciences

Volumn 118, Issue 4, 2012, Pages 408-412

  Ibrahim, Islam A A E H ^a,b   Kurose, Hitoshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Zagazig University   (Egypt)

Author keywords

Biased agonist; G protein; G protein coupled receptor; arrestin

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II (1 SARCOSINE 4 ISOLEUCINE 8 ISOLEUCINE); BETA ARRESTIN; CARVEDILOL; GPR 109A; MITOGEN ACTIVATED PROTEIN KINASE; MUSCARINIC AGENT; NICOTINIC AGENT; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE [7-34]; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SARCOSYLARGINYLVALYLTYROSYLISOLEUCYLHISTIDYLPROLYL DEXTRO ALANINE HYDROXIDE; TRV 120027; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; CHRONIC INFLAMMATION; CONFORMATIONAL TRANSITION; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84867206104     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11R10CP     Document Type: Review

References (33)

1. Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol. 2007;69:511-534.
2. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nature Rev Drug Discov. 2010;9:373-386.
3. Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, et al. β-Arrestin 2 mediates endocytosis of type III TGF-β receptor and down-regulation of its signaling. Science. 2003;301:1394-1397.
4. Lin FT, Daaka Y, Lefkowitz RJ. β-Arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor. J Biol Chem. 1998;273:31640-31643.
5. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E, et al. Nicotine induces cell proliferation by β-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest. 2006;116:2208-2217.
6. Shukla AK, Kim J, Ahn S, Xiao K, Shenoy SK, Liedtke W, et al. Arresting a transient receptor potential (TRP) channel: β-arrestin 1 mediates ubiquitination and functional down-regulation of TRPV4. J Biol Chem. 2010;285:30115-30125.
7. Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, et al. β-Arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J Biol Chem. 2006;281:1261-1273.
8. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. β-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal. 2010;125:ra46.
9. Noor N, Patel CB, Rockman HA. β-Arrestin: a signaling molecule and potential therapeutic target for heart failure. J Mol Cell Cardiol. 2011;51:534-541.
10. Ahn S, Wei H, Garrison TR, Lefkowitz RJ. Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by β-arrestins 1 and 2. J Biol Chem. 2004;279:7807-7811.
11. αq/11 coordinately activate RhoA and stress fiber formation following receptor stimulation. J Biol Chem. 2005;280:8041-8050.
12. Anthony DF, Sin YY, Vadrevu S, Advant N, Day JP, Byrne AM, et al. β-Arrestin 1 inhibits the GTPase-activating protein function of ARHGAP21, promoting activation of RhoA following angiotensin II type 1A receptor stimulation. Mol Cell Biol. 2011; 5:1066-1075.
13. Nunes KP, Rigsby CS, Webb RC. RhoA/Rho-kinase and vascular diseases: what is the link? Cell Mol Life Sci. 2010;67:3823-3836.
14. Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B, et al. Identification of β-arrestin2 as a G protein-coupled receptor-stimulated regula tor of NF-κB pathways. Mol Cell. 2004;14:303-317.
15. Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. β-Arrestin inhibits NF-κB activity by means of its interaction with the NF- κB inhibitor IκBα. Proc Natl Acad Sci U S A. 2004;101:8603-8607.
16. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of β-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A. 2006;103:1492-1497.
17. Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M, et al. A nuclear function of β-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell. 2005;123:833-847. Erratum in: Cell. 2006;124:645.
18. Shin J, Johnson JA. β-Blocker pharmacogenetics in heart failure. Heart Fail Rev. 2010;15:187-196.
19. 1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest. 2007;117:2445-2458.
20. Kim IM, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, et al. β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A. 2008; 105:14555-14560.
21. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, et al. Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A. 2003;100:10782-10787.
22. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, et al. Selectively engaging β-arrestins at the angiotensin II Type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther. 2010;335:572-579.
23. Rajagopal K, Whalen EJ, Violin JD, Stiber JA, Rosenberg PB, Premont RT, et al. β-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci U S A. 2006;103:16284-16289.
24. Gesty-Palmer D, Luttrell LM. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass? Br J Pharmacol. 2011;164:59-67.
25. Gesty-Palmer D, Flannery P, Yuan L, Corsino L, Spurney R, Lefkowitz RJ, et al. A β-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med. 2009;1:1ra1.
26. 4 receptor joins the club of 7 transmembrane domain receptors exhibiting functional selectivity. Mol Pharmacol. 2011;79:631-638.
27. 4 receptor antagonist reduces dermal inflammation and pruritus in a hapten-induced experimental model. Eur J Pharmacol. 2011;667:383-388.
28. Poulin B, Butcher A, McWilliams P, Bourgognon JM, Pawlak R, Kong KC, et al. The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner. Proc Natl Acad Sci U S A. 2010;107:9440-9445.
29. Kong KC, Butcher AJ, McWilliams P, Jones D, Wess J, Hamdan FF, et al. M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1. Proc Natl Acad Sci U S A. 2010;107:21181-21186.
30. Benyó Z, Gille A, Kero J, Csiky M, Suchánková MC, Nüsing RM, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2006;115:3634-3640.
31. Shen HC, Ding F-X, Deng Q, Wilsie LC, Krsmanovic ML, Taggart AK, et al. Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats. J Med Chem. 2009;52:2587-2602.
32. Xiao K, Sun J, Kim J, Rajagopal S, Zhai B, Villén J, et al. Global phosphorylation analysis of β-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A. 2010;107:15299-15304.
33. Christensen GL, Kelstrup CD, Lyngsø C, Sarwar U, Bøgebo R, Sheikh SP, et al. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics. 2010;9:1540-1553.